Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy

Autores de CIPF

• Raquel García García

  Autor

• Paola Leone

  Autor

• Andrea Cabrera Pastor

  Autor

• 

  Amparo Urios Lluch

  Autor

• Carla Gimenez Garzó

  Autor

• Carmina Montoliu Felix

  Autor

• 

  Vicente Felipo Orts

  Autor

Participantes ajenos a CIPF

• Mangas-Losada, A
• Ballester, MP
• Gallego, JJ
• Martinez-Pretel, JJ
• Revert, F
• Escudero-Garcia, D
• Tosca, J
• Rios, MP
• Monton, C
• Durban, L
• Aparicio, L

Grupos de Investigación

• Laboratorio de Neurobiología

  

  Jefe/a de Grupo

  Vicente Felipo Orts

• Unidad Mixta CIPF-INCLIVA de Deterioro Neurológico

Abstract

Background Minimal hepatic encephalopathy (MHE) in cirrhotic patients is associated with specific changes in parameters of the immune system reflecting a more pro-inflammatory environment than in patients without MHE. The aims of this work were to assess the effects of rifaximin treatment of cirrhotic patients with MHE on: (1) MHE; (2) intermediate (CD14(++)CD16(+)) pro-inflammatory monocytes; (3) expression of early activation marker CD69 in T lymphocytes; (4) autoreactive CD4(+)CD28(-) T lymphocytes; (5) differentiation of CD4(+) T lymphocytes to Th follicular and Th22; (6) serum IgG levels; and (7) levels of some pro-inflammatory cytokines. Methods These parameters were measured by immunophenotyping and cytokine profile analysis in 30 controls without liver disease, 30 cirrhotic patients without MHE and 22 patients with MHE. Patients with MHE were treated with rifaximin and the same parameters were measured at 3 and 6 months of treatment. We assessed if changes in these parameters are different in patients who improve MHE (responders) and those who remain in MHE (non-responders). Results Rifaximin improved MHE in 59% of patients with MHE. In these responder patients rifaximin normalized all alterations in the immune system measured while in non-responders it normalizes only IL-6, CCL20, and differentiation of T lymphocytes to Th22. Non-responder patients do not show increased expression of CD69 before treatment. Conclusions Rifaximin normalizes changes in the immune system in patients who improve MHE but not in non-responders. Some alterations before treatment are different in responders and non-responders. Understanding these differences may identify predictors of the response of MHE to rifaximin.

Keywords

• Minimal hepatic encephalopathy; Rifaximin; Immunophenotype; T lymphocytes activation